AstraZeneca beats expectations in Q3 2026 and reaffirms full-year guidance
FROM THE WIRE · FINANCE.YAHOO.COM
AstraZeneca reported third quarter 2026 results ahead of expectations, with revenue of US$16.21b, net income of US$3.12b and core EPS of US$2.79, and reaffirmed full year guidance for mid to high single digit revenue growth and low double digit core EPS growth. Management…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishThe earnings beat and reaffirmed guidance strengthen the growth outlook for the pharmaceutical group.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01AstraZeneca reported revenue of $16.21 billion and net income of $3.12 billion.
- 02Core EPS came in at $2.79, ahead of expectations.
- 03The company reaffirmed 2026 guidance for mid to high single digit revenue growth.
- 04A new restructuring plan targets annual savings of $1.5 billion.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets